What is NDC 70710-1926?

70710-1926 is the product NDC for Sodium phenylacetate and Sodium benzoate, Sodium phenylacetate 100 mg/mL; Sodium benzoate 100 mg/mL injection, solution, concentrate, listed with the FDA by Zydus Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What is the active ingredient?

Sodium phenylacetate, Sodium benzoate.

Zydus Pharmaceuticals USA Inc., NDC labeler code 70710. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Sodium phenylacetate and Sodium benzoate?

9 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Sodium phenylacetate and Sodium benzoate NDC 70710-1926

NDC codes

FDA NDC Directory

Product NDC (as listed)70710-1926Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70710-1926Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70710-1926-1	70710192601	1 VIAL in 1 CARTON (70710-1926-1) / 20 mL in 1 VIALMarketed from Sep 19, 2023

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sodium phenylacetate and Sodium benzoate
Generic name (nonproprietary): sodium phenylacetate and sodium benzoate
Active ingredients: Sodium phenylacetate — 100 mg/mLSodium benzoate — 100 mg/mL
Dosage form: Injection, Solution, Concentrate
Route: Intravenous
Labeler: Zydus Pharmaceuticals USA Inc.NDC labeler code 70710
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217526
Marketing start: Sep 19, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Ammonium Ion Binding Activity (Mechanism)Ammonium Ion Binding Activity (Mechanism)
Identifiers: Product ID 70710-1926_fd646c47-7fcd-4d60-8f6c-29e13f611c6dSPL ID fd646c47-7fcd-4d60-8f6c-29e13f611c6dSPL set ID 0f17c50f-3761-4470-bf3b-63837a287b8aRxCUI 2560228UNII 48N6U1781G, OJ245FE5EUUPC 0370710192617
Pharmacologic class: Nitrogen Binding Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N470710192601 followed by a unit qualifier and the quantity

Package 70710-1926-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 30, 2023.

Indications (excerpt from the label)

Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in paediatric and adult patients with deficiencies in enzymes of the urea cycle. ( 1 ) Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be c…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 70710-1926

What is NDC 70710-1926?: 70710-1926 is the product NDC for Sodium phenylacetate and Sodium benzoate, Sodium phenylacetate 100 mg/mL; Sodium benzoate 100 mg/mL injection, solution, concentrate, listed with the FDA by Zydus Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Sodium phenylacetate and Sodium benzoate.
What is the active ingredient?: Sodium phenylacetate, Sodium benzoate.
Who is the labeler?: Zydus Pharmaceuticals USA Inc., NDC labeler code 70710. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Sodium phenylacetate and Sodium benzoate?: 9 other product NDCs are listed under this name. See all Sodium phenylacetate and Sodium benzoate NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Sodium phenylacetate and Sodium benzoate NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Sodium phenylacetate and Sodium benzoate	Sodium phenylacetate 100 mg/mL; Sodium benzoate 100 mg/mL	Injection, Solution, ConcentrateIntravenous	Navinta LLC	68475-513	68475-0513-01
SODIUM PHENYLACETATE and SODIUM BENZOATE	Sodium phenylacetate 100 mg/mL; Sodium benzoate 100 mg/mL	Injection, Solution, ConcentrateIntravenous	Omnivium Pharmaceuticals LLC	81665-204	81665-0204-01
SODIUM PHENYLACETATE and SODIUM BENZOATE	Sodium phenylacetate 100 mg/mL; Sodium benzoate 100 mg/mL	Injection, Solution, ConcentrateIntravenous	Omnivium Pharmaceuticals LLC	81665-203	81665-0203-01
Sodium Phenylacetate and Sodium Benzoate	Sodium phenylacetate 100 mg/mL; Sodium benzoate 100 mg/mL	InjectionIntravenous	FOSUN PHARMA USA INC	72266-236	72266-0236-01
Sodium Phenylacetate and Sodium Benzoate	Sodium phenylacetate 100 mg/mL; Sodium benzoate 100 mg/mL	InjectionIntravenous	MAIA PHARMACEUTICALS	70511-102	70511-0102-20
Sodium Phenylacetate and sodium benzoate	Sodium phenylacetate 100 mg/mL; Sodium benzoate 100 mg/mL	Injection, Solution, ConcentrateIntravenous	Navinta LLC	68475-001	68475-0001-50
Sodium Phenylacetate And Sodium Benzoate	Sodium phenylacetate 100 mg/mL; Sodium benzoate 100 mg/mL	Injection, Solution, ConcentrateIntravenous	Zydus Pharmaceuticals USA Inc.	68382-396	68382-0396-01
Sodium Phenylacetate And Sodium Benzoate	Sodium phenylacetate 100 mg/mL; Sodium benzoate 100 mg/mL	Injection, Solution, ConcentrateIntravenous	MAIA PHARMACEUTICALS, INC	70511-101	70511-0101-50
SODIUM PHENYLACETATE and SODIUM BENZOATE	Sodium phenylacetate 100 mg/mL; Sodium benzoate 100 mg/mL	Injection, Solution, ConcentrateIntravenous	Ailex Pharmaceuticals, LLC	70556-100	70556-0100-50

Other NDCs under ANDA 217526

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217526
Product	Strength	Form · route	Labeler	Product NDC
Sodium phenylacetate and Sodium benzoate	Sodium phenylacetate 100 mg/mL; Sodium benzoate 100 mg/mL	Injection, Solution, ConcentrateIntravenous	Navinta LLC	68475-513